-
公开(公告)号：US11945807B2
公开(公告)日：2024-04-02
申请号：US17661909
申请日：2022-05-03
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC classification number: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US12172986B2
公开(公告)日：2024-12-24
申请号：US17059635
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US11679107B2
公开(公告)日：2023-06-20
申请号：US17046528
申请日：2019-04-11
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Andrew Cook , Dominic Reynolds , Cheng Zhong , Ryan Brawn , Shelby Ellery , Thiwanka Samarakoon , Xiang Liu , Sudeep Prajapati , Megan Sheehan , Jason T. Lowe , James Palacino
IPC: C07D405/06 , A61K31/496 , A61P35/00 , A61K9/00 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/395 , C07D313/00 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08
CPC classification number: A61K31/496 , A61K9/0053 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/191 , A61K38/208 , A61K38/2013 , A61K38/2066 , A61K38/2086 , A61K38/217 , A61K39/3955 , A61P35/00 , C07D313/00 , C07D405/06 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08 , C07B2200/05
Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy
-
公开(公告)号：US20240327535A1
公开(公告)日：2024-10-03
申请号：US18741705
申请日：2024-06-12
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/92
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
Patent Agency Ranking
公开(公告)号：US12043670B2
公开(公告)日：2024-07-23
申请号：US17339549
申请日：2021-06-04
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/92
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US11352348B2
公开(公告)日：2022-06-07
申请号：US17247117
申请日：2020-11-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61P35/00 , A61K47/68 , A61K47/60 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20220081486A1
公开(公告)日：2022-03-17
申请号：US17339549
申请日：2021-06-04
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US20220031859A1
公开(公告)日：2022-02-03
申请号：US17312320
申请日：2019-12-12
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Nathan Fishkin , Thiwanka Samarakoon , James Palacino , Kenzo Arai , Yoshihiko Kotake , Shinya Okubo , Norio Murai , Masayuki Miyano
IPC: A61K47/68 , A61K47/60 , A61P35/00 , A61K39/395 , A61K39/00 , C12Q1/6886 , C07D407/06 , C07D405/14
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a herboxidiene splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. The herboxidiene itself is also claimed. Further claims are directed to its use, and to the use of a neoantigen, generated by the herboxidiene or its ADC, or a vaccine against this neoantigen.
-
公开(公告)号：US20200255415A1
公开(公告)日：2020-08-13
申请号：US16349479
申请日：2017-11-22
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Mark Bock , Ming-Hong Hao , Manav Korpal , Vijay Kumar Nyavanandi , Xiaoling Puyang , Susanta Samajdar , Peter Gerard Smith , John Wang , Guo Zhu Zheng , Ping Zhu , Lorna Helen Mitchell , Nicholas Larsen , Nathalie Rioux , Sudeep Prajapati , Dominic Reynolds , Morgan O'Shea , Thiwanka Samarakoon
IPC: C07D413/14 , A61P35/00 , C07D231/56 , C07D401/10 , C07D401/14 , C07D401/12 , C07D413/12 , C07D403/10
Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.02 seconds)
